Schrödinger jumps on the PRMT5 bandwagon
Meanwhile, Bristol Myers Squibb hands back two mystery projects.
Triple meeting 2023 – PRMT5 has a wobble
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
Bristol puts Mirati out of its misery
The acquisition brings closure for Mirati at last, though some investors will feel disappointed.
Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.